ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2486

Clinical Performance Of 4 Methods For Detecting Latent Tuberculosis Infection (LTbI) In Patients With Active Chronic Inflammatory Arthritis Taking TNFα Blockers

Carina M F Gomes1, Maria Teresa Terreri2, Maria Isabel Pinto3, Karen Oseki3, Fernanda Spina4 and Marcelo M. Pinheiro5, 1Rheumatology Division, Universidade Federal de São Paulo, Sao Paulo, Brazil, 2Pediatrics, Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil, 3Pediatrics, Universidade Federal de São Paulo, Sao Paulo, Brazil, 4Rheumatology Division, Universidade Federal de São Paulo Unifesp/EPM, Brazil, Universidade Federal de São Paulo, Sao Paulo, Brazil, 5Brazilian Registry of Spondyloarthritis, São Paulo, Brazil

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, Psoriatic arthritis, Rheumatoid arthritis (RA), spondylarthritis and tuberculosis

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III

Session Type: Abstract Submissions (ACR)

Background/Purpose: About 5% of the Brazilian population has some chronic inflammatory arthropathy (CIA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PA) and juvenile idiopathic arthritis (JIA), and 30 to 50% of them will need to use some TNFα inhibitor to control disease activity. However, several studies have shown greater rates of active mycobacterial infections after starting of these medications. According Brazilian database, the incidence of active cases of mycobacterial infection, especially tuberculosis, has increased in patients with CIA when compared to the adult (86.93/100.000 persons-year vs. 37.48/100.000 P-Y, respectively) and pediatric Brazilian population (22.53/100.000 P-Y vs. 15.91/100.000 P-Y, respectively). It is worthy emphasizing that all of them were negative for latent tuberculosis infection (LTbI) in the first medical evaluation. Purpose:  To compare clinical performance of 4 methods for detecting LTbI in CIA patients taking TNFα blockers.

Methods: A total of 87 patients were included in this cross-sectional study, of whom 35 with RA, 35 with AS, 7 with PA and 10 JIA patients. Patients with active tuberculosis, hepatitis B or C and HIV infection were excluded. All participants answered a specific questionnaire, including details on epidemiologic data, medical history, and symptoms related to tuberculosis, as well as BCG vaccine history and socioeconomic status. Besides, they performed chest radiography and tuberculin skin test (PPD). In case of induration lower than 4 mm, the test was repeated in the contralateral forearm up to 3 weeks after the first reading (PPD-Booster). The interferon gamma specific release assays (IGRAs) were performed using Elispot (T-SPOT.TB) and Quantiferon (Quantiferon-TB GOLD).

Results: Fourteen new cases of LTBI were identified in CIA adult patients taking TNFα inhibitors (Table 1). All JIA children were negative for the 4 tests. Although the concordance between the 4 tests has been above 75%, the positivity was not associated with active tuberculosis.

Conclusion: Fourteen new cases of LTBI were identified in CIA adult patients taking TNFα inhibitors (Table 1). All JIA children were negative for the 4 tests. Although the concordance between the 4 tests has been above 75%, the positivity was not associated with active tuberculosis. Table 1. Clinical performance of 4 methods for detecting LTBI in patients taking TNFα blockers

Test for LTbI Rheumatoid Arthritis           (n=35) Ankylosing Spondylitis            (n=35) Psoriatic Arthritis          (n=7)
PPD before starting TNFα blockers 9 (25.7%) 8 (22.8%) 1 (14.2%)
PPD after starting TNFα blockers 13 (37.1%) 10 (28.5%) 3 (42.8%)
ELISPOT 12 (34.2%) 11 (31.4%) 3 (42.8%)
Quantiferon (QTF) 6 (17.1%) 7 (25.9%) 3 (42.8%)
PPD-Booster 2 (9%) 1 (4%) 0

 


Disclosure:

C. M. F. Gomes,
None;

M. T. Terreri,
None;

M. I. Pinto,
None;

K. Oseki,
None;

F. Spina,
None;

M. M. Pinheiro, None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-performance-of-4-methods-for-detecting-latent-tuberculosis-infection-ltbi-in-patients-with-active-chronic-inflammatory-arthritis-taking-tnf%ce%b1-blockers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology